BiotoxtechCo.,Ltd. Logo

BiotoxtechCo.,Ltd.

A non-clinical CRO providing GLP-compliant safety and toxicity testing for diverse industries.

086040 | KO

Overview

Corporate Details

ISIN(s):
KR7086040003
LEI:
Country:
South Korea
Address:
충청북도 청주시 청원구 오창읍 연구단지로 53, 청주시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Biotoxtech Co., Ltd. is a non-clinical Contract Research Organization (CRO) that provides comprehensive safety and toxicity evaluation services. The company conducts a wide range of Good Laboratory Practice (GLP)-compliant studies, including general toxicity, carcinogenicity, genotoxicity, safety pharmacology, immunotoxicity, and reproductive and developmental toxicity. It serves a diverse clientele developing pharmaceuticals, biomedicines, cell and gene therapies, medical devices, chemicals, agrochemicals, cosmetics, and health functional foods. Biotoxtech is recognized as a leading domestic CRO, specializing in safety pharmacology and alternatives to animal testing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-27 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 32.6 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-07-24 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-06-02 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.8 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.8 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 578.3 KB
2025-03-14 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 173.7 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.9 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 144.0 KB
2025-03-13 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 163.7 KB
2025-03-06 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 131.5 KB
2025-02-27 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.8 KB

Automate Your Workflow. Get a real-time feed of all BiotoxtechCo.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BiotoxtechCo.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BiotoxtechCo.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.